Amedica Corporation, a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, is pleased to announce a collaboration with Celling Biosciences, a leader in autologous cellular therapy technologies, to research and develop biologically enhanced implants. As part of the initial phase of the collaboration, Celling Biosciences’ team of scientists produced research indicating mesenchymal stem cells can be optimized and proliferate when using silicon nitride compared to the current PEEK and titanium biomaterial standards.
Results from the recent in vivo scientific study show that Amedica’s proprietary silicon nitride composition significantly outperformed PEEK in attachment testing of mesenchymal stem cells. Amedica’s unique silicon nitride biomaterial contains natural nano-surface topography and chemistry that play an active role in implant integration, which current trends in surface modification efforts have not replicated. The results of the study suggest the microenvironment of silicon nitride promotes better cell adhesion and compatibility with five times greater cell adhesion as compared to the PEEK material used.
With the initial research phase completed, Celling Biosciences will then translate the early findings to clinical trials in spinal and orthopedic applications. This collaborative research will further define the clinical advantages of silicon nitride in combination with stem cell-based therapies. Based on further scientific findings, the intellectual property from both partners could be leveraged to create innovative solutions that promote a robust nanotechnology.